Interactions Between Adaptable Pathogens, Drugs And The Human Host
Funder
National Health and Medical Research Council
Funding Amount
$5,727,327.00
Summary
The Centre for Clinical Immunology and Biomedical Statistics (CCIBS) represents a collaboration between Royal Perth Hospital and Murdoch University that has brought together internationally recognised expertise in clinical immunology, experimental biology and innovation in biostatistics and computing. These resources have been applied to a broad range of research issues within the broad framework of HIV and hepatitis C disease and treatment. CCIBS has become a leading centre of research excellen ....The Centre for Clinical Immunology and Biomedical Statistics (CCIBS) represents a collaboration between Royal Perth Hospital and Murdoch University that has brought together internationally recognised expertise in clinical immunology, experimental biology and innovation in biostatistics and computing. These resources have been applied to a broad range of research issues within the broad framework of HIV and hepatitis C disease and treatment. CCIBS has become a leading centre of research excellence internationally, establishing a reputation for innovative approaches to host-viral interactions that are built on a long tradition of research into the population genetics of both human and viral genomes, combined with a willingness to negotiate complex computation and statistical challenges in order to faithfully reflect dynamic biological processes at a population level. An early recognition that large and integrated repositories of genetic and clinical data are fundamental to the research success in the genomic era has also led to the creation of the single most comprehensive repository of HIV genetic sequencing data in the world. The contributions that CCIBS has made to several distinct areas of research, including understanding viral adaptation to host immune responses, the development of genetic testing to predict drug hypersensitivity reactions, and causes of antiretroviral drug-associated toxicities, have been published in prestigious journals including Science, Nature, Nature Immunology, The Lancet, Proceedings of National Academy of Sciences, and The American Journal of Human Genetics, and have also resulted in numerous international collaborations that recognise the unique attributes that CCIBS has been able to bring to the global research effort aimed at understanding fundamental aspects of HIV and hepatitis C biology and treatment.Read moreRead less
SERPINB2 IS AN INDUCIBLE HOST FACTOR INVOLVED IN ENHANCING HIV-1 TRANSCRIPTION AND REPLICATION
Funder
National Health and Medical Research Council
Funding Amount
$496,446.00
Summary
SerpinB2 is one of the most abundant proteins made at sites of inflammation. We have shown that HIV-1 infection also induces SerpinB2 and that SerpinB2 then helps the virus to replicate. In this grant we seek to understand how the virus causes this protein to be made and how this protein then increases virus replication. In the human population there are different forms of SerpinB2 and this grant seeks to determine whether these different forms affect HIV-1 replications differently. It may for i ....SerpinB2 is one of the most abundant proteins made at sites of inflammation. We have shown that HIV-1 infection also induces SerpinB2 and that SerpinB2 then helps the virus to replicate. In this grant we seek to understand how the virus causes this protein to be made and how this protein then increases virus replication. In the human population there are different forms of SerpinB2 and this grant seeks to determine whether these different forms affect HIV-1 replications differently. It may for instance be possible that an individual who has a certain form of SerpinB2 may be less susceptable to AIDS following HIV-1 infection.Read moreRead less
I am a Clinical Immunologist, Immunopathologist, clinical researcher and laboratory scientist exploring the interactions between T cell and viral infections. My area of particular interest is the mechanisms by which HIV infection subverts effective T cel
Using A Novel Assay That Detects Antigen Specific CD4+ And Regulatory T Cells To Further Understand Reconstitution Of Antigen Specific Immune Response Post Anti-retroviral Therapy In Subjects With HIV And In The Diagnosis Of Latent TB
Funder
National Health and Medical Research Council
Funding Amount
$102,780.00
Summary
The process by which the immune system recovers after commencement of therapy for HIV is not well understood. We will use a new test to monitor the immune system's ability to recognise and react to different antigens inorder to understand the factors that affect immune recovery in patients on therapy for HIV. We will also evaluate the use of this new test in the diagnosis of latent TB. Improvement in detection will lead to treatment of latent TB thus reduction of cases of active TB.
The development of cures, vaccines and better treatments for HIV/AIDS is an urgent global health priority. This team of seven groups in Sydney and Melbourne will study how HIV can lie dormant in some parts of the body, evading eradication by HIV therapy, as well as how the immune system responds to the virus. This will allow for design of novel vaccines and treatments. The researchers have skills in basic virology and immunology, and translating laboratory findings into human clinical trials.
A successful vaccine prevents infection. For HIV infection all candidate vaccines thus far have failed. From the many HIV-1 infected individuals there are a very small percentage that do not progress to disease. For these infected subjects we hypothesise that their immune responses are much better preserved and hence they will have stronger antibody responses. We have geared up our laboratory to characterise these strong antibodies and use them in making a better HIV-1 vaccine.
Current anti-HIV therapies can't cure HIV because HIV remains silent(latent) in long-lived cells. The HIV life cycle and virus production is linked to activation of the host cell, which is regulated by dendritic cells. This grant will explore how the factors controlling T cell activation and proliferation control virus expression and latency. By understanding how latent infection is established and maintained, these studies will potentially identify new ways to eliminate HIV infection.
Discovery Early Career Researcher Award - Grant ID: DE130100470
Funder
Australian Research Council
Funding Amount
$375,000.00
Summary
Understanding mechanisms and functions of evolutionary divergence in innate immune genes. Microorganisms constantly challenge the immune systems of all multi-cellular organisms, and host immune genes must be able to co-evolve with microbes in order for a species to propagate. This project will investigate how host immune genes in a species evolve to enable that species to continue.
Immune Modulatory Interventions In People With HIV And Cancer: Prevention, Treatment, And Implications For HIV Eradication.
Funder
National Health and Medical Research Council
Funding Amount
$344,644.00
Summary
People with HIV are at increased risk of many cancers. New therapies that target the immune system may be useful in treating these cancers, and may also target the cells where HIV persists thereby assisting in eradication of HIV. This research program includes three clinical studies in people with HIV and cancer: one to learn more about their immunity; one to prevent, and one to treat certain cancers by modulating the immune system. Each also explores any effect on HIV eradication.